Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study
|
|
- Fay Hensley
- 5 years ago
- Views:
Transcription
1 Anticoagulation in older people with atrial fibrillation and stroke 4. Ferro JM, Falcao I, Rodrigues G et al. Diagnosis of transient ischemic attack by the nonneurologist: a validation study. Stroke 1996; 27: Geddes JML, Fear J, Tennant A, Pickering A. Prevalence of self-reported stroke in a population in northern England. J Epidemiol Community Health 1996; 50: Wade DT. Stroke. In Stevens A, Raftery J, eds. Health Care Needs Assessment. Oxford: Radcliffe Medical Press, Wilkinson WE, Heyman A, Burch JG, Ostfield A, Lambarth DR, Leviton A. Use of a self-administered questionnaire for detection of transient cerebral ischaemic attacks: survey of elderly persons living in retirement facilities. Ann Neurol 1979; 6: O Mahony PG, Dobson R, Rodgers H, James OFW, Thomson RG. Validation of a population screening questionnaire to assess prevalence of stroke. Stroke 1995; 26: Albers GW, Caplan LR, Easton JD et al. Transient ischemic attack proposal for a new definition. N Engl J Med 2002; 347: Jones WJ, Williams LS, Meschia JF. Validating the Questionnaire for Verifying Stroke-Free Status (QVSFS) by neurological history and examination. Stroke 2001; 32: Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: Koudstaal PJ, van Gijn J, Staal A, Duivenvoorden HJ. Diagnosis of transient ischemic attacks: improvement of interobserver agreement by a check-list in ordinary language. Stroke 1986; 17: Received 12 May 2004; accepted 13 July 2004 Age and Ageing 2005; 34: doi: /ageing/afi004 Age and Ageing Vol. 34 No. 1 British Geriatrics Society 2005; all rights reserved Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study GEORGIOS TSIVGOULIS 1, KONSTANTINOS SPENGOS 1, NIKOLAOS ZAKOPOULOS 2, EFSTATHIOS MANIOS 2, VASSILIOS PEPPES 2, KONSTANTINOS VEMMOS 2 1 Department of Neurology, Eginition Hospital, University of Athens, Greece 2 Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Greece Address correspondence to: K. Spengos, Vas. Sofias 82, Athens, Greece. Fax: (+30) spengos@hol.gr Abstract Background and purpose: despite large randomised trials that demonstrated the efficacy of oral anticoagulants in the primary and secondary prevention of stroke in patients with non-valvular atrial fibrillation (AF), anticoagulation therapy remains largely under-used in older patients, who are at risk of first ever or recurrent stroke. The aim of the present study was to assess the influence of anticoagulation therapy on long-term prognosis in the oldest old stroke patients with AF after adjusting for baseline risk factors. Methods: we evaluated prospectively a consecutive series of 207 older people (>75 years) with AF and first ever ischaemic stroke. During the follow-up period (mean 88.4 months, range 3 120), the study population was under either oral anticoagulants (n = 72) or aspirin (n = 135). Death and recurrent vascular events (stroke and systemic embolism) were documented. Statistical analyses were performed by means of the Kaplan Meier product limit method and the Cox proportional hazards model. Results: the cumulative 10 year mortality and recurrence rate were 92.5% (95% CI ) and 66.1% (95% CI ), respectively. Cox regression analysis revealed increasing age, functional dependency at hospital discharge and antiplatelet versus anticoagulation therapy as independent determinants of mortality. Antiplatelet versus anticoagulation therapy was the sole determinant of vascular recurrence. Anticoagulation was associated with decreased risk of death (hazards ratio (HR) 0.47, 95% CI , P = 0.001)) and recurrent thromboembolism (HR 0.31, 95% CI , P = 0.002). 35
2 G. Tsivgoulis et al. Conclusions: our results suggest that the benefits of anticoagulation for secondary stroke prevention in AF patients extend to the oldest old. Prospective randomised clinical trials are needed to verify the potential benefit of anticoagulation in such patients. Keywords: ischaemic stroke, atrial fibrillation, anticoagulants, elderly, prognosis Introduction Non-valvular atrial fibrillation (AF) is a common cardiac arrhythmia that predisposes to left atrial thrombus formation and carries an increased risk for stroke [1]. Older people are particularly at high risk because the prevalence of AF and the risk of AF-associated stroke increase with age [2, 3]. In people over 75 years, AF is the most important single cause of ischaemic stroke (IS) [4]. Meta-analyses of randomised clinical trials have demonstrated the efficacy of anticoagulation therapy for the primary prevention of stroke in AF patients [5, 6]. In addition, the European Atrial Fibrillation Trial (EAFT) has established the value of anticoagulation for the secondary prevention of thromboembolic events [7]. Despite the preventive potential of oral anticoagulants (OA), several studies have reported that less than 50% of older patients who have clear-cut indications and no contraindications receive OA [8 12]. This low use of warfarin is driven by many factors, but physicians fear of haemorrhage is among the most important [12 14]. Moreover, older people were significantly under-represented in clinical trials with only 20% of patients being over 75 [5], although more than 50% of AF patients were in this age group in population-based trials [1]. Additional trials that focus on this specific subgroup of AF patients are warranted to define better the risks and benefits of antithrombotic therapies [4]. The aim of the present study was to assess the influence of anticoagulation therapy on long-term prognosis in stroke patients over the age of 75 and with AF after adjusting for baseline risk factors. Subjects and methods Baseline assessment This study was based on 1736 first ever stroke patients consecutively included in the Athens Stroke Registry between June 1992 and December This is a computerised prospective observational databank, gathered in a university teaching hospital, which provides tertiary care services to the urban population of Athens. Details of the stroke population evaluated over the first 5 year period and exclusion criteria have been previously described [15]. All patients were hospitalised in a five bed acute stroke unit or a general medical ward. On admission, a physician specialising in stroke examined all patients. The initial evaluation consisted of a non-contrast brain CT scan, standard blood tests, a chest X-ray and a 12-lead electrocardiogram. A second CT scan or brain MRI was performed in most cases (4 14 days later). During hospitalisation the following risk factors were documented: hypertension, diabetes mellitus, atrial fibrillation, hypercholesterolaemia, smoking, coronary artery disease, congestive heart failure and history of transient ischaemic attacks (TIA) [15]. Atrial fibrillation was classified as intermittent if electrocardiographic evidence of sinus rhythm between at least two episodes of AF during the preceding 12 months was obtained and as constant if electrocardiographic evidence of sustained AF for more than 3 weeks without intervening sinus rhythm in the preceding 12 months was obtained [16]. All patients with no evidence of intracerebral haemorrhage on the first CT scan received aspirin ( mg) on admission. According to the treating physician s decision both in the stroke unit and the general medical wards anticoagulation was initiated 1 4 weeks after ictus in medically and neurologically stable AF patients after radiographic exclusion of haemorrhagic infarct transformation. The remaining patients were treated with aspirin ( mg daily). The selection of patients for anticoagulation therapy relied heavily on their compliance, the presence of a motivated family environment and their access to anticoagulation services. The target range for anticoagulation was an international normalised ratio (INR) of using adjusted OA doses according to current recommendations [17]. We used the modified Rankin Scale adapted by the Oxfordshire Community Stroke Project to classify the functional deficit at hospital discharge [18]. Disabling strokes were defined as those with Rankin Scores of 2 5 [14, 18]. Study population We prospectively evaluated the cases fulfilling all the following criteria: (i) age over 75 years; (ii) electrocardiographically proven AF in the 12 months preceding the index event; (iii) first ever IS (347 cases fulfilled the above-mentioned three criteria); (iv) survival during hospitalisation (78 patients excluded on the basis of this criterion); (v) no echocardiographic evidence of valvular disease (eight patients excluded on the basis of this criterion); (vi) no other sources of cardiac emboli: prosthetic valves, cardiac aneurysm, myocardial infarction in the preceding 3 months, atrial myxoma, cardiothoracic ratio >0.65 (11 patients excluded on the basis of this criterion) [7]; (vii) no contraindications for OA: repeated falls, chronic alcohol habituation, recurrent syncope, uncontrolled seizure disorder, uncontrolled hypertension, gastrointestinal or genitourinary bleeding in the preceding 6 months and daily use of non-steroidal antiinflammatory drugs (21 patients excluded on the basis of this criterion) [16]. Patients who were transferred to rehabilitation centres (n=17) or lost (n=5) during follow-up were excluded from further evaluation. The final study population consisted of 207 patients over 75 years with stroke and AF. 36
3 Anticoagulation in older people with atrial fibrillation and stroke Follow-up All survivors were followed up prospectively at month 1, 3 and 6, and every 6 months thereafter, up to 10 years after stroke by a study investigator and a trained nurse. Followup was routinely performed in our outpatient clinic or in the patient s place of residence in cases with severe handicap. The outcome events of interest were death and recurrent vascular event (stroke and systemic embolism). To determine recurrent vascular events and causes of death we evaluated all the available information obtained from death certificates, hospital records, physicians notes in private practice, necropsy findings and the patients clinical presentation at the regular follow-up assessments. Recurrent stroke was defined as a cerebrovascular event of sudden onset and lasting for more than 24 hours subsequent to the initial stroke that clearly resulted in a new or an increase in an existing neurological deficit [7, 19]. The diagnosis of systemic embolism was clinically defined as abrupt vascular insufficiency of limbs or internal organs associated with clinical or radiological evidence of arterial occlusion, in the absence of other likely mechanisms (atherosclerosis) [19]. The causes of death were divided into the following subgroups: (i) death due to infections (pulmonary infections, urinary infections and septic shock); (ii) death due to vascular causes (myocardial infarction, cardiac arrhythmia, acute pulmonary oedema or heart failure, systemic embolism, recurrent stroke); (iii) death due to other cause (e.g. renal failure, cancer); (iv) undetermined cause of death. Statistical analyses Statistical analysis was performed to compare patients on OA (group A) and on aspirin (group B) in terms of demographics, pre-existing conditions and functional outcome at hospital discharge. Dichotomous or categorical variables were compared with the chi-squared test and continuous variables were compared with the unpaired t-test or Mann Whitney U test as indicated. Continuous data are presented as mean (SD) and non-continuous data as percentages. The Kaplan Meier product limit method was used to estimate the probability of survival and recurrent vascular events after 10 years from the index event. To evaluate which factors contribute to long-term mortality and vascular recurrence, a univariate Cox s proportional hazards model was used. Those factors that contributed to the outcome in the univariate analyses at P values <0.1 (because of the risk of type II error due to low statistical power in such an analysis) were included in the multivariate model as candidate variables. In the final multivariate analyses, statistical significance was achieved if P < Associations are presented as hazards ratios (HR) with their corresponding 95% confidence intervals (95% CI). The Statistical Package for Social Science (SPSS Inc., version 10.0 for Windows) was used for statistical analyses. Results The present cohort consisted of 97 men and 110 women (mean age 80.4 ± 3.0 and 80.5 ± 2.9 years, respectively). The detailed characteristics of the entire collective are presented in Table 1. Hypertension was the most common risk factor (73.9%), while intermittent AF was highly prevalent (31.9%). Most patients (72.5%) were dependent at hospital discharge. Only 20 patients (9.7%) were on OA before the index event, while 56 subjects (27.1%) were receiving antiplatelets. Anticoagulation was provided in 72 patients (34.8%, group A) at discharge and during follow-up, while in the remaining 135 subjects (65.2%, group B) aspirin therapy was administered. No statistically significant differences were documented between the two groups in terms of baseline characteristics (Table 1). During mean follow-up of 88.4 months (range 3 120), 132 (63.8%) deaths and 58 (28.0%) recurrent vascular events (52 strokes and 6 cases of systemic embolism) were documented. Intracranial haemorrhage was identified by means of CT in two patients on OA and in one on aspirin. Vascular disease was the major underlying cause of mortality, accounting for 46.9% of deaths (22.7% secondary to stroke and 24.2% from cardiovascular diseases). Infections were the second cause of mortality (21.2%), while the cause of death remained undetermined in 20.5%. The cumulative 10 year mortality and recurrence rate were 92.5% (95% CI ) and 66.1% (95% CI ), respectively. The annual event rate of vascular recurrence was estimated at 5.5% in group A and 16.3% in group B, while the annual rate of intracranial haemorrhage was 1.1% and 0.3%, respectively. In order to identify independent predictors of long-term mortality and recurrence we performed Cox proportional hazard analyses (Tables 2 and 3). In the initial univariate analyses, age, sex, AF pattern, functional outcome at discharge and antithrombotic therapy were related to mortality. The Table 1. Baseline characteristics of the study population (n = 207) Characteristics Group A (n = 72) Group B (n = 135) P value Demographics/risk factors Mean age (SD, years) 79.9 (2.8) 80.7 (3.1) Mean time of hospitalisation 14.0 (6.8) 13.9 (7.5) (SD, days) Male gender Hypertension Diabetes mellitus Hypercholesterolaemia Smoking Coronary heart disease Intermittent atrial fibrillation Recent onset atrial fibrillation ( 1 year) Heart failure Previous transient ischaemic attack Functional dependency at hospital discharge (mrs: 2 5) Continuous data are presented as mean (SD) and non-continuous data as percentages. mrs, modified Rankin Scale. 37
4 G. Tsivgoulis et al. Table 2. Univariate and multivariate Cox proportional hazard analyses determining the effect of different factors on mortality Dependent variable Univariate analysis *P < 0.001, P <0.05, **P < 0.1, P <0.01. mrs, modified Rankin Scale. Multivariate analysis Age (per 10 year increase) 2.72 ( )* 2.03 ( ) Gender Male 1.0 Female 1.61 ( ) 1.27 ( ) Hypertension 1.14 ( ) Diabetes mellitus 1.09 ( ) Hypercholesterolaemia 0.98 ( ) Smoking 0.69 ( ) Coronary heart disease 1.35 ( ) Pattern of atrial fibrillation Constant Intermittent 0.70 ( )** 0.72 ( ) Heart failure 1.21 ( ) Previous transient ischaemic attack 0.94 ( ) Functional outcome at discharge (mrs) Grade Grade ( )* 2.12 ( )* Antithrombotic therapy Antiplatelets Anticoagulation 0.45 ( )* 0.47 ( ) Table 3. Univariate and multivariate Cox proportional hazard analyses determining the effect of different factors on recurrence Dependent variable *P <0.001, **P <0.1, P <0.01. mrs, modified Rankin Scale. Univariate analysis Multivariate analysis Age (per 10 year increase) 1.19 ( ) Gender Male 1.0 Female 1.58 ( )** 1.34 ( ) Hypertension 0.85 ( ) Diabetes mellitus 1.54 ( ) Hypercholesterolaemia 1.28 ( ) Smoking 0.89 ( ) Coronary heart disease 1.02 ( ) Pattern of atrial fibrillation Constant Intermittent 0.60 ( )** 0.58 ( ) Heart failure 1.16 ( ) Previous transient ischaemic attack 0.90 ( ) Functional outcome at discharge (mrs) Grade Grade ( ) Antithrombotic therapy Antiplatelets Anticoagulation 0.32 ( )* 0.31 ( ) multivariate model revealed only increasing age, dependency and anticoagulation therapy as significantly independent outcome predictors. AF pattern, female sex and antithrombotic therapy were associated with vascular recurrence on univariate analysis, but only antithrombotic therapy was retained as independent determinant of recurrence in the multivariate model. The HR associated with OA versus aspirin for long-term mortality and recurrence was 0.47 (95% CI , P = 0.001) and 0.31 (95% CI , P = 0.002), respectively. Discussion Efficacy and safety of OA for secondary prevention in AF patients have been established by the EAFT [7]. However, in that study, age was the main reason for ineligibility, accounting for 55% of the exclusions [7]. Subgroup analysis of a review of five primary prevention trials suggested that warfarin did reduce stroke in patients over age 75, but it was based on only 24 events [5]. As a result, the evidence for the effectiveness of anticoagulation in older AF patients is less impressive. Furthermore, several surveys have demonstrated that older age is a deterrent of anticoagulation independent of severity of stroke and bleeding risk [8 12], suggesting that many physicians remain unconvinced of the net benefit of OA to older people [20]. Hence, our data provide additional information about the value of anticoagulation in secondary prevention in this specific age subgroup. The principal finding of this work is that after adjusting for known risk factors, anticoagulation therapy independently decreases the risk of recurrent vascular events by more than two-thirds and halves the risk of long-term mortality in AF stroke survivors over age 75. It should be noted though that our assessment of the effect of OA on long-term prognosis is observational and raises the issue of randomised clinical trials. The BAFTA study is currently being conducted in the UK and will provide further evidence of the risks and benefits of warfarin versus aspirin for stroke prevention among older people in a primary care setting [21]. We observed an annual event rate of vascular recurrence of 5.5% in the coumadin-treated group, which is higher than reported by the EAFT (4%) [7]. On the other hand, our results are in keeping with the annual recurrence rate (5.1%) reported in a prospective cohort study which evaluated the efficacy of anticoagulation for secondary prevention in 288 elderly AF patients (mean age 76 years) [22]. The rate of recurrent vascular events in the aspirin-treated group of our cohort (16.3% per year) was higher than that in the EAFT (10%) [7], but closer to that (20%) observed among high-risk older patients in the SPAF I III trials [23]. The under-use of OA in older AF patients is mainly caused by the fear of intracerebral haemorrhage [12 14]. In the SPAF II trial, the only primary prevention trial especially focusing on 385 older (>75 years) AF patients, the high rate of intracranial haemorrhage in the anticoagulant-treated group (1.8% per year) offset the reduction in IS [24]. In contrast, a meta-analysis of pooled data (223 cases) from other primary prevention trials found a substantially lower rate of intracranial haemorrhage in this age subgroup (0.3% per year) [25]. The documented rate (1.1% per year) in our cohort lies in the middle of the above-mentioned values. 38
5 Anticoagulation in older people with atrial fibrillation and stroke This difference could be attributed to the significantly wider range for the intensity of anticoagulation in SPAF II (upper INR range 4.5) in comparison with other trials [20, 24]. Our results also indicate that anticoagulation therapy is independently inversely associated with long-term mortality, in contrast to the findings of the EAFT which found no significant benefit of OA on mortality [7]. Hospital-based studies have established cardiac disease and recurrent stroke as the major causes of death in stroke survivors with AF [19, 26]. An autopsy study verified that AF is an important cause of fatal first ever or recurrent IS in older people [27]. The efficacy of anticoagulants in preventing recurrent stroke and systemic embolism may therefore translate into lower longterm mortality rates in this specific age subgroup of stroke survivors. Apart from anticoagulation therapy, our data identified age and the degree of post-stroke handicap as independent predictors of mortality. These results are in agreement with previous reports supporting age as the most robust predictor of death within 1 5 years after IS [28, 29]. Functional status at discharge has been acknowledged as a predictor of long-term mortality [29]. The pattern of AF has not emerged as an independent outcome predictor in multivariate analyses of our study population, despite its association with decreased stroke risk and mortality in the initial univariate analyses. This finding is in line with previous reports suggesting that intermittency of rhythm does not appear independently to influence stroke risk when other risk factors are considered [5, 30]. Certain limitations of the present report need to be addressed. First, our assessment of the effect of OA on longterm recurrence and mortality is observational and therefore subject to selection bias. Even though functional dependency at discharge was similar in the two groups, it is likely that patients selected to receive coumadin were more able, motivated and generally fitter. Another limitation is related to the potential observer s bias during follow-up, affecting the documentation of recurrent vascular events, although these were mostly devastating or fatal and in most cases confirmed by means of hospital records and autopsy findings. Furthermore, we cannot provide detailed data concerning the patients compliance with OA, the intensity of anticoagulation and possible complications. On the other hand, our dataset has a number of strengths. The observation period was longer than in the EAFT and SPAF trials. Although randomisation was not performed, no significant differences concerning baseline factors were documented between both groups. Finally, the influence of anticoagulation on long-term prognosis was assessed after controlling for age, sex, major vascular risk factors, dependency and comorbidities. In conclusion, our results suggest that anticoagulation therapy is an independent predictor of decreased long-term recurrence and mortality even after taking into account all known prognostic factors in older people with AF and recent IS. Although the risk of intracranial haemorrhage while receiving OA increases with age [24], so does the stroke risk [23]. People over 75 with AF and IS are considered as high risk by all the risk stratification schemes [1, 23]. These patients consequently sustain the largest proportion of cardioembolic strokes and have the largest relative and absolute risk reduction in stroke by warfarin compared with aspirin [1,4]. Our findings indicate that in older patients, the risk of stroke when not receiving OA appears to outweigh the risk of intracranial haemorrhage when receiving OA. The case of wider but judicious use of anticoagulation in older people is strengthened by this study, which shows that anticoagulation for secondary stroke prevention is feasible and effective in such patients. Key points Antiplatelets versus oral anticoagulants are independent determinants of mortality and vascular recurrence in older patients with atrial fibrillation. Anticoagulation is associated with decreased risk of death. The benefits of anticoagulation for secondary stroke prevention in patients with atrial fibrillation extend to the oldest old. Prospective randomised clinical trials are needed to verify the potential benefit of anticoagulation in older patients. Acknowledgements The authors wish to thank Ms Mary Batsara and Mrs Athina Peppa for their assistance in data collection. There is no conflict of interests. References 1. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999; 131: Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001; 32: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342: Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998; 352: Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk 39
6 G. Tsivgoulis et al. factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131: Deplanque D, Corea F, Arquizan C et al. Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? SAFE I Study Investigators. Heart 1999; 82: Lamassa M, Di Carlo A, Pracucci G et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001; 32: McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155: Chatap G, Giraud K, Vincent JP. Atrial fibrillation in the elderly: facts and management. Drugs Aging 2002; 19: York M, Agarwal A, Ezekowitz M. Physicians attitudes and the use of oral anticoagulants: surveying the present and envisioning future. J Thromb Thrombolysis 2003; 16: Vemmos KN, Takis CE, Georgilis K et al. The Athens stroke registry: results of a five-year hospital-based study. Cerebrovasc Dis 2000; 10: Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest 1992; 102: 426S 33S. 18. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 1990; 53: Sandercock P, Bamford J, Dennis M et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project). BMJ 1992; 305: Marine JE, Goldhaber SZ. Controversies surrounding longterm anticoagulation of very elderly patients in atrial fibrillation. Chest 1998; 113: Mant JW, Richards SH, Hobbs FD et al. Midlands Research Consortium of General Practice. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN ]. BMC Cardiovasc Disord 2003; 26: Evans A, Perez I, Yu G, Kalra L. Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. Stroke 2000; 31: Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999; 30: Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med 1996; 156: Connolly S. Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: Candelise L, Pinardi G, Morabito A. Mortality in acute stroke with atrial fibrillation. The Italian Acute Stroke Study Group. Stroke 1991; 22: Yamanouchi H, Tomonaga M, Shimada H, Matsushita S, Kuramoto K, Toyokura Y. Nonvalvular atrial fibrillation as a cause of fatal massive cerebral infarction in the elderly. Stroke 1989; 20: Kammersgaard LP, Jorgensen HS, Reith J, Nakayama H, Pedersen PM, Olsen TS. Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study. Age Ageing 2004; 33: Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O Fallon WM, Wiebers DO. Ischemic stroke subtypes: a populationbased study of functional outcome, survival, and recurrence. Stroke 2000; 31: Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000; 35: Received 20 May 2004; accepted 22 September
The effectiveness of a modified version of the Wilkinson questionnaire in screening for TIA and minor stroke in the United Kingdom
A. Wilson et al. 21. Taylor MT, Banerjee B, Alpar EK. The epidemiology of fractured femurs and the effect of these factors on outcome. Injury 1994; 25: 641 4. 22. Whiting P, Joseph CA, Zambon M, Nunn M,
More informationA trial fibrillation (AF) is a common arrhythmia that is
679 PAPER Atrial fibrillation as a predictive factor for severe stroke and early death in 15 831 patients with acute ischaemic stroke K Kimura, K Minematsu, T Yamaguchi, for the Japan Multicenter Stroke
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationOccurrence and Characteristics of Stroke Events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) Study
ORIGINAL INVESTIGATION Occurrence and Characteristics of Stroke Events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) Study David G. Sherman, MD; Soo G. Kim, MD;
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationjournal of medicine The new england Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation abstract
The new england journal of medicine established in 1812 september 11, 2003 vol. 349 no. 11 Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation Elaine M.
More informationAntithrombotic Therapy in Patients with Atrial Fibrillation
Antithrombotic Therapy in Patients with Atrial Fibrillation June Soo Kim, M.D., Ph.D. Department of Medicine Cardiac & Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationReducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA
DECEMBER 21 VOL. 27 SUPPL. 1 A SUPPLEMENT TO www.fedprac.com Reducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA Diagnosing and Treating Atrial Fibrillation in the VHA
More informationThe randomized study of efficiency and safety of antithrombotic therapy in
.. [ ] 18 150 160 mg/d 2 mg/d INR 2.0 3.0( 75 INR 1.6 2.5) 704 369 335 420 59.7% 63.3 9.9 19 2 24 2.7% 6.0% P =0.03 OR 0.44 95% CI 0.198 0.960 56% 62% 1.8% 4.6% P =0.04 OR 0.38 95% CI 0.147 0.977 52% 10.6%
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationV. Roldán, F. Marín, B. Muiña, E. Jover, C. Muñoz-Esparza, M. Valdés, V. Vicente, GYH. Lip
PLASMA VON WILLEBRAND FACTOR LEVELS ARE AN INDEPENDENT RISK FACTOR ADVERSE EVENTS IN HIGH RISK ATRIAL FIBRILLATION PATIENTS TAKING ORAL ANTICOAGULATION THERAPY V. Roldán, F. Marín, B. Muiña, E. Jover,
More informationSummative Assessment Audit Project. Project Number 02
Summative Assessment Audit Project Project Number 02 AUDIT TITLE: Aspirin and Warfarin prophylaxis of thromboembolism in elderly patients with Atrial Fibrillation. What is the title of your audit project?
More informationUS FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation
Press Release For non-us Healthcare Media Boehringer Ingelheim GmbH Corporate Communications US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationIntroduction. Keywords: Infrainguinal bypass; Prognosis; Haemorrhage; Anticoagulants; Antiplatelets.
Eur J Vasc Endovasc Surg 30, 154 159 (2005) doi:10.1016/j.ejvs.2005.03.005, available online at http://www.sciencedirect.com on Risk of Major Haemorrhage in Patients after Infrainguinal Venous Bypass Surgery:
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding
More informationAntithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)
Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase
More informationDepartment of Neurology, Mackay Memorial Hospital, Taipei, Taiwan
Neurology Asia 2010; 15(1) : 11 17 Antithrombotic treatment before stroke onset and stroke severity in patients with atrial fibrillation and first-ever ischemic stroke: An observational study Helen L Po
More informationAPPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL
APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH
More informationComorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia
Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationComparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial Fibrillation
Journal of the American College of Cardiology Vol. 51, No. 8, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.09.065
More informationATRIAL fibrillation is one of the most common cardiac arrhythmias and has
Distinct Increase in Hematocrit Associated with Paroxysm of Atrial Fibrillation Shigeru OKUNO, MD*, Terunao ASHIDA, MD, Aya EBIHARA, MD, Takao SUGIYAMA, MD, and Jun FUJII, MD SUMMARY In a previous study
More informationEchocardiographic Predictors of Stroke in Patients With Atrial Fibrillation
ORIGINAL INVESTIGATION Echocardiographic Predictors of Stroke in Patients With Atrial Fibrillation A Prospective Study of 1066 Patients From 3 Clinical Trials Atrial Fibrillation Investigators: Atrial
More informationRedgrave JN, Coutts SB, Schulz UG et al. Systematic review of associations between the presence of acute ischemic lesions on
6. Imaging in TIA 6.1 What type of brain imaging should be used in suspected TIA? 6.2 Which patients with suspected TIA should be referred for urgent brain imaging? Evidence Tables IMAG1: After TIA/minor
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationStroke is the third-leading cause of death and a major
Long-Term Mortality and Recurrent Stroke Risk Among Chinese Stroke Patients With Predominant Intracranial Atherosclerosis Ka Sing Wong, MD; Huan Li, MD Background and Purpose The goal of this study was
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationCurrent role of low molecular weight heparin in the treatment of acute. ischemic stroke.
International Journal of Advances in Medicine Singh K. Int J Adv Med. 2017 Dec;4(6):1599-1604 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20175174
More informationA2.1: Main model assumptions
Appendix 2: Main assumptions and structure of the economic model We assumed that before the introduction of DOACs standard of care for AF patients was warfarin. For patients on warfarin as first-line treatment,
More informationAtrial fibrillation is a potent risk factor for ischemic
Thirty-Day Mortality After Ischemic Stroke and Intracranial Hemorrhage in Patients With Atrial Fibrillation On and Off Anticoagulants Margaret C. Fang, MD, MPH; Alan S. Go, MD; Yuchiao Chang, PhD; Leila
More informationDo Not Cite. Draft for Work Group Review.
Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationU-shaped relationship between mortality and admission blood pressure in patients with acute stroke
Journal of Internal Medicine 2004; 255: 257 265 U-shaped relationship between mortality and admission blood pressure in patients with acute stroke K. N. VEMMOS 1, G. TSIVGOULIS 2, K. SPENGOS 2, N. ZAKOPOULOS
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationNon-commercial use only
Italian Journal of Medicine 2016; volume 10:202-206 Embolic stroke of undetermined source: a retrospective analysis from an Italian Stroke Unit Marco Masina, 1 Annalena Cicognani, 1 Carla Lofiego, 2 Simona
More informationGeorge Ntaios, Konstantinos Vemmos, Gregory Y.H. Lip, Elena Koroboki, Efstathios Manios, Anastasia Vemmou, Ana Rodríguez Campello, Valentina Arnao,
George Ntaios, Konstantinos Vemmos, Gregory Y.H. Lip, Elena Koroboki, Efstathios Manios, Anastasia Vemmou, Ana Rodríguez Campello, Valentina Arnao, Valeria Caso, Maurizio Paciaroni, Exuperio Diez-Tejedor,,
More informationIschemic Stroke in Critically Ill Patients with Malignancy
Ischemic Stroke in Critically Ill Patients with Malignancy Jeong-Am Ryu 1, Oh Young Bang 2, Daesang Lee 1, Jinkyeong Park 1, Jeong Hoon Yang 1, Gee Young Suh 1, Joongbum Cho 1, Chi Ryang Chung 1, Chi-Min
More informationThe objective of this study was to determine the longterm
The Natural History of Lone Atrial Flutter Brief Communication Sean C. Halligan, MD; Bernard J. Gersh, MBChB, DPhil; Robert D. Brown Jr., MD; A. Gabriela Rosales, MS; Thomas M. Munger, MD; Win-Kuang Shen,
More informationWarfarin Management-Review
Warfarin Management-Review December 18, 2012 Elaine M. Hylek, MD, MPH Director, Thrombosis Clinic and Anticoagulation Service Boston University Medical Center Areas for Discussion Implications of time
More informationAtrial fibrillation patient decision aid: Antithrombotic therapy
Atrial fibrillation patient decision aid: Antithrombotic therapy What this decision aid is for This decision aid is intended to assist health professionals in consultations with patients with atrial fibrillation
More information<INSERT COUNTRY/SITE NAME> All Stroke Events
WHO STEPS STROKE INSTRUMENT For further guidance on All Stroke Events, see Section 5, page 5-15 All Stroke Events Patient Identification and Patient Characteristics (I 1) Stroke
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Hart RG, Diener H-C, Coutts SB, et al,
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationORIGINAL INVESTIGATION. New Transient Ischemic Attack and Stroke
ORIGINAL INVESTIGATION New Transient Ischemic Attack and Stroke Outpatient Management by Primary Care Physicians Larry B. Goldstein, MD; John Bian, MS; Gregory P. Samsa, PhD; Arthur J. Bonito, PhD; Linda
More informationAtrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal
Atrial Fibrillation Etiologies and Treatment Shawn Liu Learner Centered Learning Goal Pathophysiology Defined by the absence of coordinated atrial systole Results from multiple reentrant electrical waves
More informationCanadian Best Practice Recommendations for Stroke Care. (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management
Canadian Best Practice Recommendations for Stroke Care (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management Reorganization of Recommendations 2008 2006 RECOMMENDATIONS: 2008 RECOMMENDATIONS:
More informationStarting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective
Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective Cathy Sila MD George M Humphrey II Professor and Vice Chair of Neurology Director, Comprehensive Stroke Center
More informationSupplementary Online Content
Supplementary Online Content Huang W-Y, Singer DE, Wu Y-L, et al. Association of intracranial hemorrhage risk with non vitamin K antagonist oral anticoagulant use vs aspirin use: a systematic review and
More informationHospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate Anticoagulation
Journal of the American College of Cardiology Vol. 46, No. 9, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.077
More informationProfessor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham
New Guidelines for SPAF Professor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham Stroke prevention and atrial fibrillation Epidemiology of atrial fibrillation How common is it?
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationLuisa Vinciguerra. Ictus recidivanti
Luisa Vinciguerra Ictus recidivanti Recurrent Strokes DEFINITION Population-based studies exclude strokes: - within 28 or 21 days of the incident event - events in the same vascular territory as the original
More informationORIGINAL INVESTIGATION
Are the Results of Randomized Controlled Trials on Anticoagulation in With Atrial Fibrillation Generalizable to Clinical Practice? Andrew Evans, MRCP; Lalit Kalra, PhD, FRCP ORIGINAL INVESTIGATION Background:
More informationNonvalvular atrial fibrillation is an important independent
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis Robert G. Hart, MD; Oscar Benavente, MD; Ruth McBride, BS; and Lesly A. Pearce, MS Purpose: To characterize
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
More informationSubjects with nonrheumatic atrial fibrillation
1000 Risk Factors for Stroke and Other Embolic Events in Patients With Nonrheumatic Atrial Fibrillation Kenneth M. Flegel, MD, MSc, FACP, and James Hanley, PhD Factors associated with stroke and other
More informationPeripheral Arterial Occlusive Disease- The Challenge in patients with diabetes
Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes Ashok Handa Reader in Surgery and Consultant Surgeon Nuffield Department of Surgery University of Oxford Introduction Vascular
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationWeighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Albert L. Waldo, MD, PhD (Hon) The Walter H. Pritchard Professor of Cardiology, Professor of Medicine,and
More informationSpeakers. 2015, American Heart Association 1
Speakers Lee Schwamm, MD, FAHA Executive Vice Chairman of Neurology, Massachusetts General Hospital Director, Stroke Service and Medical Director, MGH TeleHealth, Massachusetts General Hospital Director,
More informationStudy period Total sample size (% women) 899 (37.7%) Warfarin Aspirin
Table S2 Sex- specific differences in oral anticoagulant prescription for stroke prevention in AF Total sample size (% women) Anticoagulant(s) studied Gage (2000) 1 Missouri, USA Discharged during 597
More informationEvidence-based study on antithrombotic therapy in patients at risk of a stroke with paroxysmal atrial fibrillation
EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: 413-418, 2013 Evidence-based study on antithrombotic therapy in patients at risk of a stroke with paroxysmal atrial fibrillation XINJUN CHEN 1*, RONGHUA WAN 2*,
More informationSubclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study Meagan Sullivan, PharmD PGY2 Cardiology Pharmacy Resident University of Chicago Medicine
More informationORIGINAL INVESTIGATION. Prevalence and Quality of Warfarin Use for Patients With Atrial Fibrillation in the Long-term Care Setting
ORIGINAL INVESTIGATION Prevalence and Quality of Warfarin Use for Patients With Atrial Fibrillation in the Long-term Care Setting Danny McCormick, MD, MPH; Jerry H. Gurwitz, MD; Robert J. Goldberg, PhD;
More informationAtrial fibrillation is common among elderly patients 1,2
Perindopril-Based Blood Pressure Lowering Reduces Major Vascular Events in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack Hisatomi Arima, MD; Robert G. Hart, MD; Sam Colman,
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationUse of Anticoagulants in Geriatrics: Current Evidence and Special Considerations
Use of Anticoagulants in Geriatrics: Current Evidence and Special Considerations Aryn You, PharmD Assistant Professor, Pharmacy Practice The Daniel K. Inouye College of Pharmacy Aida Wen, MD Associate
More informationT he value of antihypertensive treatment in protection
1360 PAPER Twenty four hour pulse pressure predicts long term recurrence in acute stroke patients G Tsivgoulis, K Spengos, N Zakopoulos, E Manios, K Xinos, D Vassilopoulos, K N Vemmos... See end of article
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationA COhort of antithrombotic use and. atrial fibrillation in Thailand (COOL AF Thailand)
A COhort of antithrombotic use and Optimal INR Level in patients with nonvalvular atrial fibrillation in Thailand (COOL AF Thailand) Prevalence of Atrial Fibrillation Number of AF Patients Predicted to
More informationAnticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar
Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationThe Impact of Smoking on Acute Ischemic Stroke
Smoking The Impact of Smoking on Acute Ischemic Stroke Wei-Chieh Weng, M.D. Department of Neurology, Chang-Gung Memorial Hospital, Kee-Lung, Taiwan Smoking related mortality Atherosclerotic vascular disease
More informationStroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital
Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationAtrial Fibrillation Key Messages
Atrial Fibrillation Key Messages Dr Matthew Fay Westcliffe Medical Practice National Clinical Lead NHS Improvement www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Clinical Events
More informationDisclosures. An Update on TIA and Minor Stroke. The Agenda PROGNOSIS PATHOPHYSIOLOGY GUIDELINES AND PROVEN MANAGEMENT STRATEGIES AGGRESSIVE TREATMENT
Disclosures An Update on TIA and Minor Stroke Dr. Johnston is principal investigator for the POINT trial, sponsored by the NIH but with drug and placebo contributed by Sanofi-Aventis. S. Claiborne Johnston,
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationAtrial fibrillation is common among elderly
209 Atrial Fibrillation After in the Elderly Paul J. Friedman, MD, FRACP To examine the relationship between atrial fibrillation and mortality after stroke, we studied 186 men and 167 women from the Waikato
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationThrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE
Thrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE ESUS Progression of haematoma Anticoagulation Large ICH
More informationMaking Choices. Treatments to Prevent Stroke in Patients with Atrial Fibrillation. Physician s Manual
Making Choices Treatments to Prevent Stroke in Patients with Atrial Fibrillation Physician s Manual Table of Contents Purpose of the decision aid................................... 2 Purpose of this physician
More informationTHE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease
THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS 1. Cardiovascular Disease Cardiovascular disease is considered to have developed if there was a definite manifestation
More informationDirect oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece
Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece Disclosures Scholarships: European Stroke Organization; Hellenic Society of Atherosclerosis.
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationNONVALVULAR ATRIAL FIBRILlation
CLINICAL CARDIOLOGY Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation An Individual Patient Meta-analysis Carl van Walraven, MD, MSc, FRCPC Robert G. Hart, MD Daniel E. Singer, MD Andreas
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationDeclaration of conflict of interest. None to declare
Declaration of conflict of interest None to declare Risk management of coronary artery disease Arrhythmias and diabetes Hercules Mavrakis Cardiology Department Heraklion University Hospital Crete, Greece
More informationIs Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationAtrial fibrillation (AF) effects 2.2 million individuals
Prevalence of Atrial Fibrillation and Antithrombotic Prophylaxis in Emergency Department Patients Phillip A. Scott, MD; Arthur M. Pancioli, MD; Lisa A. Davis, RN, MSN, CCRC; Shirley M. Frederiksen, MS,
More informationThe rate of stroke in nonvalvular atrial fibrillation (AF)
Arrhythmia/Electrophysiology Selecting Patients With Atrial Fibrillation for Anticoagulation Stroke Risk Stratification in Patients Taking Aspirin Brian F. Gage, MD, MSc; Carl van Walraven, MD, FRCPC,
More information